[go: up one dir, main page]

HUE064978T2 - A petefészekrák kezelésének módszerei - Google Patents

A petefészekrák kezelésének módszerei

Info

Publication number
HUE064978T2
HUE064978T2 HUE17821262A HUE17821262A HUE064978T2 HU E064978 T2 HUE064978 T2 HU E064978T2 HU E17821262 A HUE17821262 A HU E17821262A HU E17821262 A HUE17821262 A HU E17821262A HU E064978 T2 HUE064978 T2 HU E064978T2
Authority
HU
Hungary
Prior art keywords
ovarian cancer
treatment methods
treatment
methods
ovarian
Prior art date
Application number
HUE17821262A
Other languages
English (en)
Inventor
Mary Lynne Hedley
Robert Martell
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787744&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE064978(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of HUE064978T2 publication Critical patent/HUE064978T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HUE17821262A 2016-06-29 2017-06-29 A petefészekrák kezelésének módszerei HUE064978T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356461P 2016-06-29 2016-06-29
US201662402427P 2016-09-30 2016-09-30
US201762470141P 2017-03-10 2017-03-10

Publications (1)

Publication Number Publication Date
HUE064978T2 true HUE064978T2 (hu) 2024-04-28

Family

ID=60787744

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17821262A HUE064978T2 (hu) 2016-06-29 2017-06-29 A petefészekrák kezelésének módszerei

Country Status (24)

Country Link
US (5) US20180311224A1 (hu)
EP (2) EP4302835A3 (hu)
JP (2) JP7083760B2 (hu)
KR (2) KR20230042136A (hu)
CN (1) CN109640992A (hu)
AU (1) AU2017290244B2 (hu)
BR (1) BR112018077492A2 (hu)
CA (1) CA3029671C (hu)
DK (1) DK3478286T3 (hu)
ES (1) ES2969816T3 (hu)
FI (1) FI3478286T3 (hu)
HR (1) HRP20240136T1 (hu)
HU (1) HUE064978T2 (hu)
IL (1) IL263925B2 (hu)
LT (1) LT3478286T (hu)
MX (1) MX394062B (hu)
NZ (1) NZ749413A (hu)
PL (1) PL3478286T3 (hu)
PT (1) PT3478286T (hu)
RS (1) RS65180B1 (hu)
SG (1) SG11201811564QA (hu)
SI (1) SI3478286T1 (hu)
SM (1) SMT202400105T1 (hu)
WO (1) WO2018005818A1 (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
JP2019533458A (ja) 2016-11-01 2019-11-21 アナプティスバイオ インコーポレイティッド プログラム死1(pd−1)に対する抗体
MX2019008207A (es) 2017-01-09 2019-12-11 Tesaro Inc Métodos para tratar el cáncer con anticuerpos anti-pd-1.
SG10201913083SA (en) 2017-01-09 2020-03-30 Tesaro Inc Methods of treating cancer with anti-tim-3 antibodies
EA201992177A1 (ru) * 2017-03-27 2020-02-25 Тесаро, Инк. Композиции на основе нирапариба
SG11201909807TA (en) 2017-04-24 2019-11-28 Tesaro Inc Methods of manufacturing of niraparib
BR112019023591A2 (pt) * 2017-05-09 2020-05-26 Tesaro, Inc. Terapias de combinação para tratar câncer
BR112019024135A2 (pt) 2017-05-18 2020-06-02 Tesaro, Inc. Terapias de combinação para o tratamento de câncer
EP3687505A1 (en) 2017-09-26 2020-08-05 Tesaro Inc. Niraparib formulations
CN111372607A (zh) 2017-09-30 2020-07-03 特沙诺有限公司 用于治疗癌症的联合疗法
US11801240B2 (en) 2017-10-06 2023-10-31 Tesaro, Inc. Combination therapies and uses thereof
BR112020015909A2 (pt) * 2018-02-05 2020-12-15 Tesaro, Inc. Formulações pediátricas de niraparib e métodos de tratamento pediátrico
WO2019195443A1 (en) * 2018-04-04 2019-10-10 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor
JP7472115B2 (ja) 2018-10-03 2024-04-22 テサロ, インコーポレイテッド ニラパリブ塩
WO2020072796A1 (en) 2018-10-03 2020-04-09 Tesaro, Inc. Crystalline forms of niraparib freebase
US10395772B1 (en) 2018-10-17 2019-08-27 Tempus Labs Mobile supplementation, extraction, and analysis of health records
EP3857555A4 (en) 2018-10-17 2022-12-21 Tempus Labs DATA-BASED CANCER RESEARCH AND TREATMENT SYSTEMS AND METHODS
WO2020142583A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
US11705226B2 (en) 2019-09-19 2023-07-18 Tempus Labs, Inc. Data based cancer research and treatment systems and methods
WO2021011609A1 (en) * 2019-07-15 2021-01-21 Tesaro, Inc. Methods of treating ovarian, fallopian tube and peritoneal cancer
US11295841B2 (en) * 2019-08-22 2022-04-05 Tempus Labs, Inc. Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data
KR20220123064A (ko) * 2019-12-31 2022-09-05 킨네이트 바이오파마 인크. Cdk12/13 억제제에 의한 암 치료
JP2023510853A (ja) * 2020-01-13 2023-03-15 グラダリス,インコーポレイティド Gm-csfをコードするポリヌクレオチドと追加薬剤を用いてがんを治療する方法
CA3196725A1 (en) * 2020-10-29 2022-05-05 Johannes FAHRMANN Methods for the detection and treatment of ovarian cancer
KR20230114557A (ko) 2022-01-25 2023-08-01 서울대학교산학협력단 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법
EP4479050A1 (en) 2022-02-15 2024-12-25 Tesaro, Inc. Use of niraparib for the treatment of brain cancer
CN115253066A (zh) * 2022-07-21 2022-11-01 湖南安泰康成生物科技有限公司 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置
CN116092631A (zh) * 2023-01-17 2023-05-09 湖南安泰康成生物科技有限公司 铁死亡诱导剂与电场联用的肿瘤治疗系统
WO2025061057A1 (en) * 2023-09-19 2025-03-27 Impact Therapeutics (Shanghai) , Inc Use of a parp inhibitor in maintenance therapy of ovarian cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
JP2011503071A (ja) * 2007-11-12 2011-01-27 バイパー サイエンシズ,インコーポレイティド Parp阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療
BRPI0906020A2 (pt) 2008-01-08 2015-06-30 Merck Sharp & Dohme Sais farmaceuticamente aceitáveis de 2-{4-[ (3s) - piperidina-3-il ] fenil} -2h - indazol - 7 - carboxamida, uso e método de tratamento
EP3862440A1 (en) 2010-06-18 2021-08-11 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
CA2807823C (en) 2010-08-24 2023-02-07 The Brigham And Women's Hospital, Inc. Methods for predicting anti-cancer response
WO2014052550A1 (en) * 2012-09-27 2014-04-03 Thomas Jefferson University Use of parp inhibitors to treat breast cancer
PT2981624T (pt) * 2013-04-05 2020-03-23 Myriad Genetics Inc Métodos para avaliar deficiência na recombinação homóloga e prever resposta a tratamento para cancro
WO2015108986A1 (en) * 2014-01-16 2015-07-23 Clovis Oncology, Inc. Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
US10238630B2 (en) * 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
US20150344968A1 (en) * 2014-05-30 2015-12-03 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Methods for determining parp inhibitor and platinum resistance in cancer therapy
CN105384695B (zh) * 2014-08-22 2019-12-20 四川海思科制药有限公司 嘧啶衍生物及其制备方法和在医药上的应用
US11154538B2 (en) * 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer

Also Published As

Publication number Publication date
KR102510996B1 (ko) 2023-03-16
JP7083760B2 (ja) 2022-06-13
LT3478286T (lt) 2024-04-25
US20180311224A1 (en) 2018-11-01
EP4302835A3 (en) 2024-03-20
RS65180B1 (sr) 2024-03-29
AU2017290244B2 (en) 2023-03-02
DK3478286T3 (da) 2024-01-29
MX394062B (es) 2025-03-19
SI3478286T1 (sl) 2024-03-29
SMT202400105T1 (it) 2024-05-14
US20220395493A1 (en) 2022-12-15
CA3029671C (en) 2023-08-15
IL263925B1 (en) 2023-08-01
IL263925B2 (en) 2023-12-01
KR20230042136A (ko) 2023-03-27
EP3478286A1 (en) 2019-05-08
WO2018005818A1 (en) 2018-01-04
BR112018077492A2 (pt) 2019-04-09
JP2019524690A (ja) 2019-09-05
CN109640992A (zh) 2019-04-16
IL263925A (en) 2019-01-31
FI3478286T3 (fi) 2024-03-14
SG11201811564QA (en) 2019-01-30
US20240058319A1 (en) 2024-02-22
CA3029671A1 (en) 2018-01-04
NZ749413A (en) 2023-05-26
US20220175752A1 (en) 2022-06-09
PT3478286T (pt) 2024-01-31
EP3478286B1 (en) 2024-01-03
AU2017290244A1 (en) 2019-01-24
ES2969816T3 (es) 2024-05-22
MX2018016193A (es) 2019-06-10
EP3478286A4 (en) 2020-03-18
HRP20240136T1 (hr) 2024-04-12
EP4302835A2 (en) 2024-01-10
KR20190029618A (ko) 2019-03-20
JP2022031478A (ja) 2022-02-18
PL3478286T3 (pl) 2024-04-22
US20220175751A1 (en) 2022-06-09

Similar Documents

Publication Publication Date Title
HUE064978T2 (hu) A petefészekrák kezelésének módszerei
IL254760A (en) Method for treating cancer
IL255189A0 (en) Methods of treating cancer
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
HUE050831T2 (hu) Daganatkezelési módszerek a CD3XCD20 bispecifikus antitest használatával
EP3474854A4 (en) DRUG ASSOCIATIONS FOR THE TREATMENT OF CANCER
HUE053744T2 (hu) A rák kombinált kezelése
MA45129A (fr) Traitements du cancer
LT3490560T (lt) Būdas prostatos vėžiui gydyti naudojant niraparibą
IL284875A (en) Lasofoxifene treatment of breast cancer
EP3546020A4 (en) CANCER TREATMENT APPARATUS
EP3413927A4 (en) CANCER THERAPY
IL268463A (en) Cancer treatment
HUE040167T2 (hu) Rákkezelés
IL265751B (en) Immunogenic compounds for cancer therapy
LT3383385T (lt) Melflufeno dozavimo režimas vėžio atveju
EP3785729C0 (en) OVARIAN CANCER VACCINES
EP3576791A4 (en) CALRETICULIN-MEDIATION CANCER TREATMENT
IL246558A0 (en) New methods of cancer treatment
EP3484477A4 (en) CANCER TREATMENT
DE112014006578A5 (de) Führungseinrichtung
EP3523659C0 (en) MULTI-PROTEASE PROCESS
DK3407909T3 (da) Cancerbehandling
IL272379A (en) Methods of treating cancer by inhibiting setd2
DE112014006618A5 (de) Führungseinrichtung